Introduction
ovarian cancer, HRD
OVARIAN CANCER
Homologous recombination deficiency (HRD) associated with inactivation of mainly PARPi have been extensively tested in patients with ovarian cancer. Six phase III clinical trials have demonstrated that maintenance with a PARPi, with or without bevacizumab (bev), following platinum-based therapy in patients with newly diagnosed advanced ovarian cancer (AOC) improved progression-free survival (PFS) for BRCAmut and for BRCAwt HRD cases [The European HRD ENGOT initiative (EHEI) is a unique collaboration of European academic laboratories aiming to provide new reliable biomarkers for HRD in AOC to select patients who benefit from PARPi ± bev in the first-line maintenance [